Golimumab 200 mg

BIOLOGICAL2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Colitis, Ulcerative

Phase 2

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

CompletedNCT00487539

Janssen Research & Development, LLCColitis, Ulcerative

Start: 2007-08-31End: 2010-10-31Updated: 2014-02-17

Phase 3

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

CompletedNCT00488631

Janssen Research & Development, LLCColitis, Ulcerative

Start: 2007-09-30End: 2015-02-28Updated: 2016-04-26

Related Papers

Low Occurrence of Colectomy With Long-Term (up to 4 Years) Golimumab Treatment in Patients With Moderate-to-Severe Active Ulcerative Colitis: Data From the PURSUIT Maintenance and Long-Term Extension Studies

Crohn s & Colitis 3602023-07-014 citations

Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland

Therapeutic Advances in Gastroenterology2022-01-018 citations

Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.

2020-01-2216 citations

Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data

Journal of Crohn s and Colitis2019-03-0116 citations

A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials

Journal of Crohn s and Colitis2019-01-2418 citations

Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension

Journal of Crohn s and Colitis2018-06-1734 citations

Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis

Alimentary Pharmacology & Therapeutics2015-06-2985 citations

Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

2013-06-14530 citations

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

2013-06-02701 citations